Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi Aber - so what would be the vetting process for this nominated shareholder? How would we trust them with insider knowledge etc.? It's fine if they have a sufficient number of shares (is it 5% or 10% you need to get a seat on the board?) but otherwise what criteria would they need to have - a business degree? Otherwise they may be more of a hindrance than a help.
As much as we can complain on here there is absolutely nothing going to happen with SDC 1801 until full data results are released. That is the meat on the bone.
How we progress after these results are realised, we will be notified thereof.
Aussies have been good and expedient so far, as such not contemplating any unexpected delays. Sareum have money to pay the fees.
Ideally as l see it continue to phase 2a in Oz.
No bl00dy hold ups with our understaffed, overworked, inexperienced MHRA employees.
News can come anytime from.now until.end of H1.
Regards and enjoy the rise when it comes.
I'd say the answer is more nuanced. The Board does have some experienced deal makers in Owen and Parker but I don't think they have done any deals outside or with SAR since joining the board. The other issue is the lack of funds. SAR are always short of funds, it is the nature of being an AIM minnow. It's like having a Royal Flush in poker but not having enough cash to stake yourself in the game. We will always have to blink first. The last factor is the AIM drag. We all know that AIM minnows struggle with fair valuations. We'd probably be valued in the hundreds of millions already on NASDAQ. There is nothing we can do about it now as I'm sure there are many hoops to jump through to get a listing. Now imagine Tim M and Parker rocking into a meeting with some really good 1a data but only enough cash in the bank to see this t
year out and undervalued before even starting negotiations. They know the value of our compounds but beggars can't be choosers. IMO, we'll get a licence with good backend milestones and a decent upfront that is enough to keep the lights on and push 1802 into clinics and hopefully a bit left over so the 1802 negotiations can be more productive. IMO 1801 could be worth up to £800 million in milestones but they will all be p3 and commercialisation. for 1802, depending on the indications we could be looking at double the 1801 milestones. It's all bio bucks until phase 3 but if 737 is in play, then you are looking at 2 billion just for getting to the end of trials. Double or triple that valuation if they get approved for market. I doubt any of us will still be here for that but the market will work out a valuation for us while we wait.
Afternoon Brighty - I know there have been some good deals in our sector but are we convinced that our current management structure could broker such deals ? ... or possibly have they had a number of offers which would have been accepted by the majority of shareholders but have been rejected as they are holding out for possibly unrealistic higher values ? .. We all know that the comms link is broken / almost non-existent and unfortunately the shareholders currently have no visibility of any of the deal discussions. Personally, based on their poor managerial performance and lack of ownership of the SP crash and RF disaster, or apology to shareholders, I would like to have seen the shareholders getting more visibility of future decisions by the appointment of a nominated shareholder to the BOD discussions under NDA to uphold the interests of the shareholders (given the recent bailout to save the company) .. which is what Dr Owens was supposed to do .. and I say 'supposed to do' as we never heard him voice any concerns regarding consolidation, RF, SP Collapse etc etc
There does need to be change !!! We, the shareholders do need better representation as I do feel the BOD are too weak and poor in all but the science ...
This is only my opinion and much is unknown due to the continued lack of communication from our BOD
Exactly and it's not just AZ signing Phase 1 licencing deals recently. In the last year Eli Lilly paid Confo Therapeutics $40 million US Dollars in an upfront payment for its Phase 1 clinical trial candidate CFTX-1554. As part of the transaction Eli Lilly also agreed a total package of $590 million US Dollars in potential milestone payments and tiered royalties.....
Good luck, Brighty
2 lots of BED & ISAS gone through (15K and 74K) .. all 4 trades showing as sells which skews the picture
I was under the impression P1a / P1b was a fluid trial same as a 2a / 2b trial, as in if you you stop after P1a for any reason e.g. lack of funds or other reason then you cant restart a P1b at a later date and the only remaining option is a P2a.
Most trials are 1 then 2. Think the board originally chose 1a,1b because the value of deals would have been higher with good 1b data. This resulting 2a pivot is another reason I think a licence is inbound. No reason to do a 1b if you have the cash to go straight into 2.
Afternoon, quick question is the latest Edison report dated 03/04/24? Just want to clarify I’m reading the latest report
Hi Basil - it'd be interesting to know how many drugs developed by large pharma are able to skip P1b, not too many I suspect. I hope news of our intent is spreading through the pharma grapevine and we attract a major as a partner. That would put us firmly on the radar when it comes to 1802.
Any hint of good news and this will rise up quicker than a bad girls nighty
AstraZeneca has a track record of buying in to P1 clinical trials, especially once the topline data has been released. Another excellent example is Eccogene who were paid $185m upfront 5 months ago by AstraZeneca. This followed encouraging preliminary results from Eccogene's Phase I trial of ECC5004. In addition, Eccogene could receive up to an additional $1.825bn in future clinical, regulatory, and commercial milestones and tiered royalties on product sales. AZ could swoop in with a licencing deal for SDC-1801 if the preliminary results are good.
Easy multibag some like there 10% some invest and have a little patience
Watch this space it’s in demand and will get more and more in demand as we go higher
GLA
It's not just licencing deals that interest AZ at the P1 stage. e.g. TeneoTwo was acquired 18 months ago by AZ for its Phase I clinical-stage T-cell engager TNB-486. In summary, AZ paid $100m cash up front for TeneoTwo plus R&D-related milestone payments of up to $805m and additional contingent commercial-related milestone payments of up to $360m. i.e. A total of up to $1.265 billion. There is so much M&A activity these days with phase 1 candidates, both in on-licencing and takeover transactions. Sareum could be next.
Can only assume it's traders seeing SAR was in the top 5 risers of the day and jumping on board. Selling as soon as they made a couple of quid.
Long list of buys followed by almost equally long list of sells. Christ, are holders really that keen to get out on a 3.5p rise?
27.22p dont be fooled, this is in demand
Morning Bobbler - I had looked at Boehringer Ingelheim before but wrote them off as they're wholly privately owned so I presumed there would be no shares available to offer i.e. with a revenue of $9bn and no shares in circulation as such, how do we value circa 136000 shares in the company?
That all said, I'm puzzled by the following link - https://annualreport.boehringer-ingelheim.com/2023/letter/shareholder/index.html
If anyone can read or access it, good luck.
Regards.
I'm thinking that there are a few RF shares left and the mm's have let the shareprice rise this morning before resuming selling and giving the impression that we are running out of steam in order to encourage further selling. Don't be taken in by this. Not long to go though
The buys where bout 300k to good now only 50k so they have got a decent chunk of sellers already, let's see if any more interest at 29p if so it's the 30s today
Hoping that the profit takers don't kick this back down too much.
Didn't take much buying at all to get back to 29p on ask
Another key point to factor in is that we've not had a negative outcome in any of our research / trials to date.
For example:
* The June 2019 data showed 100% regression of tumours in lung cancer
* The Workman / Garrett March 2020 report showed that SRA 737 when synthesised with gemcitabine had extremely encouraging results
* We've also had the data from the UKRI project which showed that SDC-1801 was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib. The bull run up to that UKRI announcement in July 2001 saw the SAR share price climb in a few months x 6 from 1.5p (75p now) to over 9p (450p now). I am expecting a similar re-rate on positive P1a data. i.e. x 6 from here is over 150p. That's a x 15 for those that bought in to the 10p WRAP offer. It's possible and we know it's happened before.....
Good luck, Brighty
Something must be on the way, confirmation of RF being out maybe?
Looks like RF have cleared